Highlights Aileron Therapeutics, Inc.

Equities

ALRN

US00887A2042

Market Closed - Nasdaq Other stock markets 21:00:00 28/06/2024 BST			5-day change	1st Jan Change
2.77 ^USD	-4.48%		-11.50%	-9.14%

06-18	Certain Warrants of Aileron Therapeutics, Inc. are subject to a Lock-Up Agreement Ending on 18-JUN-2024.	CI
06-18	Certain Common Stock of Aileron Therapeutics, Inc. are subject to a Lock-Up Agreement Ending on 18-JUN-2024.	CI

Highlights

Unlock all the news: Be the first to know and act before the market!

100% Free Registration

Aileron Therapeutics, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2024	05-15	CI
Aileron Therapeutics Closes Direct Offering of Shares, Warrants	05-03	MT
Aileron Therapeutics, Inc. Announces Positive Data from Cohort 1 of the Phase 1b Clinical Trial of LTI-03 in Idiopathic Pulmonary Fibrosis	05-01	CI
Aileron Therapeutics, Inc. Reports Earnings Results for the Full Year Ended December 31, 2023	04-15	CI
Aileron Therapeutics, Inc. Reports Earnings Results for the Fourth Quarter Ended December 31, 2023	04-15	CI
Aileron Therapeutics Acquires Lung Therapeutics in Stock-for-Stock Deal	31/10/23	MT
Aileron Therapeutics, Inc. acquired Lung Therapeutics, Inc.	30/10/23	CI
Aileron Therapeutics, Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2023	13/10/23	CI
Aileron Therapeutics, Inc. Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2023	11/08/23	CI
Aileron Therapeutics, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2023	08/05/23	CI
Aileron Therapeutics Announces Exploration of Strategic Alternatives	21/02/23	CI
Aileron Therapeutics Announces Termination of Phase 1b Breast Cancer Chemoprotection Trial and Exploration of Strategic Alternatives	21/02/23	CI
Aileron Therapeutics Regains Compliance With Nasdaq's Minimum Bid Price Requirement	30/11/22	MT
Aileron Therapeutics Launches One-for-20 Reverse Stock Split	10/11/22	MT
Aileron Therapeutics, Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2022	01/11/22	CI
Aileron Therapeutics Announces Oral Presentation of Non-Clinical Data Demonstrating ALRN-6924 Protected Human Hair Follicles and Their Stem Cells from Chemotherapy-Induced Damage at the European Society for Dermatological Research Annual Meeting 2022	30/09/22	CI
Aileron Therapeutics, Inc. Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2022	15/08/22	CI
Aileron Therapeutics Outlines Strategy to Strengthen Phase 1b Clinical Trial of ALRN-6924 in Patients with p53-Mutated Breast Cancer	01/08/22	CI
Aileron Therapeutics Announces Interim Data from Phase 1b Chemoprotection Trial of ALRN 6924 in Patients with p53-Mutated Non-Small Cell Lung Cancer and Confirms Development Path for ALRN-6924 Focused on p53-Mutated Breast Cancer	29/06/22	CI
Aileron Therapeutics Announces First Patients Treated in Phase 1B Trial of ALRN-6924 in Patients with p53-Mutated Neoadjuvant Breast Cancer	19/05/22	CI

No results for this search

All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Highlights Aileron Therapeutics, Inc.

Equities

ALRN

US00887A2042

Highlights

Filters